TriSalus Life Sciences (TLSIW) Cash from Financing Activities (2022 - 2026)

TriSalus Life Sciences (TLSIW) has 5 years of Cash from Financing Activities data on file, last reported at $42.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 337.5% year-over-year to $42.4 million; the trailing twelve-month figure through Mar 2026 stood at $63.5 million (up 42.62% YoY), and the FY2025 full-year result was $30.8 million, down 18.91% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $42.4 million, up from $277000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $42.4 million in Q1 2026 and bottomed at $43000.0 in Q4 2023.
• The 5-year median for Cash from Financing Activities is $5.9 million (2022), against an average of $10.5 million.
• The widest annual swing landed in 2023, when Cash from Financing Activities plunged 99.27%; it then surged 6862.79% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $5.9 million in 2022, then slumped by 99.27% to $43000.0 in 2023, then soared by 6862.79% to $3.0 million in 2024, then plunged by 90.75% to $277000.0 in 2025, then soared by 15201.44% to $42.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $42.4 million (Q1 2026), $277000.0 (Q4 2025), and $82000.0 (Q3 2025), per Business Quant data.

Peer Comparison